36727-17-0

Basic information

• Product Name: 1,4-Benzenedicarboxylic acid, 2-methoxy-, dimethyl ester
• CAS NO: 36727-17-0
• Molecular Formula: C11H12O5
• Molecular Weight: 224.213
• Mol File: 36727-17-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,4-Benzenedicarboxylic acid, 2-methoxy-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Benzenedicarboxylic acid, 2-methoxy-, dimethyl ester(36727-17-0)
• EPA Substance Registry System: 1,4-Benzenedicarboxylic acid, 2-methoxy-, dimethyl ester(36727-17-0)

Safety Data

• Hazardous Substances Data: 36727-17-0(Hazardous Substances Data)

Upstream product

• 636-94-2 2-hydroxyterephthalic acid 
• 74-88-4 methyl iodide 
• 586-35-6 2-bromo-1,4-benzenedicarboxylic acid 
• 6342-72-9 dimethyl hydroxyterephthalate 
• 6482-24-2 2-Bromoethyl methyl ether 
• 867-89-0 1-dimethylamino-1-methoxyethylene 
• 2166-24-7 pyridazine-3,6-dicarboxylic acid dimethyl ester 
• 67-56-1 methanol 
• 5156-00-3 2-methoxyterephthalic acid 
• 186581-53-3 diazomethane 

Downstream Products

• 492458-31-8 2-methoxyterephthalohydrazide 
• 79304-99-7 3-t-butyl-1-(7-methoxy<2,2,9,9-D4><2,2>paracyclophan-4-yl)-5--phenylverdazyl 
• 79237-19-7 3-t-butyl-1-(7-methoxy<2,2,9,9-D4><2.2>paracyclophan-4-yl)-5--phenylformazan 
• 79305-00-3 3-t-butyl-1-(7-methoxy<2,2-D2><2,2>paracyclophan-4-yl)-5-phenylverdazyl 
• 79237-20-0 3-t-butyl-1-(7-methoxy<2,2-D2><2.2>paracyclophan-4-yl)-5-phenylformazan 
• 79236-97-8 methyl 4-(acetoxymethyl)-3-methoxybenzoate 
• 79237-00-6 1,4-bis(chloro--methyl)-2-methoxybenzene 
• 79237-01-7 1-chloromethyl-4-chloro--methyl-2-methoxybenzene 
• 79236-98-9 1-hydroxymethyl-4-hydroxy--methyl-2-methoxybenzene 
• 79236-95-6 1,4-bis(hydroxy--methyl)-2-methoxybenzene 
• 79236-96-7 2-methoxy-4-(hydroxymethyl)-3-methoxybenzoate 
• 5156-00-3 2-methoxyterephthalic acid 

Relevant articles and documents

DIMER COMPOUNDS, AND USE IN BINDING TOXIC REPEATS OF RNA

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are dimeric inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

Defect Engineering into Metal-Organic Frameworks for the Rapid and Sequential Installation of Functionalities

Postsynthetic treatments are well-known and important functionalization tools of metal-organic frameworks (MOFs). Herein, we have developed a practical and rapid postsynthetic ligand exchange (PSE) strategy using a defect-controlled MOF. An increase in the number of defects amounts to MOFs with enhanced rates of ligand exchange in a shorter time frame. An almost quantitative exchange was achieved by using the most defective MOFs. This PSE strategy is a straightforward method to introduce a functionality into MOFs including bulky or catalytically relevant moieties. Furthermore, some mechanistic insights into PSE were revealed, allowing for a sequential ligand exchange and the development of multifunctional MOFs with controlled ligand ratios.

BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS

-